Pembrolizumab Plus CRT Followed by Surgery in Upper ESCC

Summary

Through a prospective, single-center, single-arm, phase Ib/II study, we aim to explore the safety and feasibility of a new treatment mode for upper esophageal cancer, which is that pembrolizumab combined with chemoradiotherapy as neoadjuvant therapy and then followed by radical surgery.

Timeline

Start

2022-08-01

Primary completion

2023-12-01

Completion

2024-12-01

Drugs

Indications